Immuneering reports Q4 EPS (58c), consensus (44c)
Reports cash, cash equivalents and marketable securities as of December 31 were $36.1M compared with $85.7M as of December 31, 2023. These ...
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...
Immuneering Corporation: Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...
Managed Healthcare Executive4d
Study Finds Adherence to Annual Lung Cancer Screening Linked to Higher Detection Rates
Researchers found that adherence to the first and second annual screenings was 61% and 51%, respectively, with higher lung ...
Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.